

AMENDMENTS TO THE CLAIMS

1. (Currently amended) A method of administering sumatriptan or a pharmaceutically acceptable salt thereof to a mammal, comprising spraying the oral mucosa of the mammal with a propellant free buccal spray composition for transmucosal administration of sumatriptan a pharmaceutically acceptable salt thereof comprising: sumatriptan or a pharmaceutically acceptable salt thereof in an amount of between 0.001 and 60 percent by weight of the total composition; and a polar solvent in an amount between 30 and 99.69 percent by weight of the total composition.

2. (Currently amended) The composition method of claim 1, further comprising a taste mask and/or flavoring agent in an amount of between 0.1 and 10 percent by weight of the total composition.

3. (Currently amended) The composition method of claim 2, wherein the polar solvent is present in an amount between 37 and 98.58 percent by weight of the total composition, the sumatriptan or a pharmaceutically acceptable salt thereof is present in an amount between 0.005 and 55 percent by weight of the total composition, and the taste mask and/or flavoring agent is present in an amount between 0.5 and 8 percent by weight of the total composition.

4. (Currently amended) The composition method of claim 3, wherein the polar solvent is present in an amount between 60.9 and 97.06 percent by weight of the total composition, the sumatriptan or a pharmaceutically acceptable salt thereof is present in an amount between 0.01 and 40 percent by weight of the total composition, and the taste mask and/or flavoring agent is present in an amount between 0.75 and 7.5 percent by weight of the total composition.

5. (Currently amended) The ~~composition~~ method of claim 1, wherein the polar solvent is selected from the group consisting of polyethylene glycols having a molecular weight between 400 and 1000, C₂ to C₈ mono- and poly-alcohols, and C₇ to C₁₈ alcohols of linear or branched configuration.

6. (Currently amended) The ~~composition~~ method of claim 1, wherein the polar solvent comprises polyethylene glycol.

7. (Currently amended) The ~~composition~~ method of claim 1, wherein the polar solvent comprises ethanol.

8. (Currently amended) The ~~composition~~ method of claim 2, wherein the flavoring agent is selected from the group consisting of synthetic or natural oil of peppermint, oil of spearmint, citrus oil, fruit flavors, sweeteners, and mixtures thereof.

9. (Currently amended) The ~~composition~~ method of claim 1, comprising sumatriptan succinate.

10. (Canceled).

11. (Currently amended) The method of claim ~~[[9]]~~1, wherein the amount of the spray is predetermined.

Claims 12-23 (Canceled).

24. (Currently amended) A method of administering sumatriptan or a pharmaceutically acceptable salt thereof to a mammal, comprising spraying the oral mucosa of the mammal with a propellant free buccal spray composition ~~for transmucosal administration of sumatriptan or a pharmaceutically acceptable salt~~

~~thereof~~ comprising: sumatriptan or a pharmaceutically acceptable salt thereof in an amount between 0.005 and 55 percent by weight of the total composition; and a non-polar solvent in an amount between 30 and 99.69 percent by weight of the total composition.

25. (Currently amended) The ~~composition~~ method of claim 24, further comprising a taste mask and/or flavoring agent in an amount between 0.1 and 10 percent by weight of the total composition.

26. (Currently amended) The ~~composition~~ method of claim 25, wherein the flavoring agent is selected from the group consisting of synthetic or natural oil of peppermint, oil of spearmint, citrus oil, fruit flavors, sweeteners, and mixtures thereof.

27. (Currently amended) The ~~composition~~ method of claim 24, wherein the solvent is selected from the group consisting of (C₂-C₂₄) fatty acid (C₂-C₆) esters, C₇-C₁₈ hydrocarbons of linear or branched configuration, C₂-C₆ alkanoyl esters, and triglycerides of C₂-C₆ carboxylic acids.

28. (Currently amended) The ~~composition~~ method of claim 27, wherein the solvent is a triglyceride.

29. (Currently amended) The ~~composition~~ method of claim 24, comprising sumatriptan succinate.

30. (Canceled).

31. (Currently amended) The method of claim ~~[[30]]~~24, wherein the amount of the spray is predetermined.

Claims 32-43 (Canceled).

44. (Currently amended) A method of administering sumatriptan or a pharmaceutically acceptable salt thereof to a mammal, comprising spraying the oral mucosa of the mammal with a buccal spray composition for transmucosal administration of sumatriptan or a pharmaceutically acceptable salt thereof comprising: sumatriptan or a pharmaceutically acceptable salt thereof in an amount between 0.2 and 10 percent by weight of the total composition; and a polar solvent comprising propylene glycol and ethanol in an amount between 50 and 99.69 percent by weight of the total composition.

45. (Currently amended) A method of administering sumatriptan or a pharmaceutically acceptable salt thereof to a mammal, comprising spraying the oral mucosa of the mammal with a propellant free buccal spray composition for transmucosal administration of sumatriptan or a pharmaceutically acceptable salt thereof comprising: sumatriptan or a pharmaceutically acceptable salt thereof in an amount of between 0.001 and 60 percent by weight of the total composition; and a mixture of a polar solvent and a non-polar solvent in an amount of between 30 and 99.69 percent by weight of the total composition, wherein the ratio of the polar solvent to the non-polar solvent ranges from 1:99 to 99:1.

46. (Currently amended) The ~~composition~~ method of claim 45, further comprising a taste mask and/or flavoring agent in an amount of between 0.1 and 10 percent by weight of the total composition.

47. (Currently amended) The ~~composition~~ method of claim 46, wherein the polar solvent is present in an amount between 37 and 98.58 percent by weight of the

total composition, the sumatriptan or a pharmaceutically acceptable salt thereof is present in an amount between 0.005 and 55 percent by weight of the total composition, and the taste mask and/or flavoring agent is present in an amount between 0.5 and 8 percent by weight of the total composition.

48. (Currently amended) The ~~composition~~ method of claim 47, wherein the polar solvent is present in an amount between 60.9 and 97.06 percent by weight of the total composition, the sumatriptan or a pharmaceutically acceptable salt thereof is present in an amount between 0.01 and 40 percent by weight of the total composition, and the taste mask and/or flavoring agent is present in an amount between 0.75 and 7.5 percent by weight of the total composition.

49. (Currently amended) The ~~composition~~ method of claim 45, wherein the polar solvent is selected from the group consisting of polyethylene glycols having a molecular weight between 400 and 1000, C₂ to C₈ mono- and poly-alcohols, and C₇ to C₁₈ alcohols of linear or branched configuration and the non-polar solvent is selected from the group consisting of (C₂-C₂₄) fatty acid (C₂-C₆) esters, C₇-C₁₈ hydrocarbons of linear or branched configuration, C₂-C₆ alkanoyl esters, and triglycerides of C₂-C₆ carboxylic acids.

50. (Currently amended) The ~~composition~~ method of claim 46, wherein the flavoring agent is selected from the group consisting of synthetic or natural oil of peppermint, oil of spearmint, citrus oil, fruit flavors, sweeteners, and mixtures thereof.

51. (Currently amended) The ~~composition~~ method of claim 45, comprising sumatriptan succinate.

52. (Canceled).

53. (Currently amended) The method of claim ~~[[52]]45~~, wherein the amount of the spray is predetermined.

Claims 54-62 (Canceled).

63. (Currently amended) ~~[[A]]~~The method of claim 1, further comprising treating migraines in a patient, comprising spraying the oral mucosa of the patient with a therapeutically effective amount of the buccal spray ~~of claim 1~~.

64. (Canceled).

65. (Currently amended) ~~[[A]]~~The method of claim 24, further comprising treating migraines in a patient, comprising spraying the oral mucosa of the patient with a therapeutically effective amount of the buccal spray ~~of claim 24~~.

66. (Canceled).

67. (Currently amended) ~~[[A]]~~The method of claim 45, further comprising treating migraines in a patient, comprising spraying the oral mucosa of the patient with a therapeutically effective amount of the buccal spray ~~of claim 45~~.

68. (Canceled).